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SUPPLEMENTARY NOTES
ABSTRACT
Prostate cancer (PCa) metastasis represents the worst outcome that eventually kills the patient. Although many PCa cell-intrinsic molecules and end-organ factors have been implicated in the metastatic dissemination of PCa cells, the role of primary tumor microenvironment and the nat ure of the metastatic PCa cells remain poorly defined. By establishing a reliable and quantifiable experimental PCa metastasis model in NOD/SCID mice, we have found that PCa cells implanted orthotopically (i.e., in the prostate) metastasize much more extensively and widely than those implanted ectopically (i.e., subcutaneously or s.c). Microarray -based gene expression profiling reveals that the orthotopically implanted human PCa cells upregulate several classes of genes that have been intimately implicated in metastasis. These and many other preliminary observations allow us to HYPOTHESIZE that PCa cells reciprocally interact with the host cells to establish a proinflammatory microenvironment highly conducive to PCa metastasis and that metastatic PCa cells a re endowed with CSC properties. By now we have accomplished all goals in Aims 1 and 2. Our lab recently relocated from the MD Anderson Cancer Center to Roswell Park Cancer Institute in Buffalo. We request a 6 -month no-cost extension to wrap up a critical set of experiments testing the possibility that HOXB9 regulates PCa metastasis in a context-and model-dependent manner. 
SUBJECT TERMS
What was accomplished under these goals:
A. Accomplishment of all goals in Aim 1. See last year's Progress Report.
B. Accomplishment of all goals in Aim 2.
By now we have completed this Aim. From last year's Progress Report, we proposed to test several combinatorial marker profiles as potentially superior mPCSC markers (to single markers). Our lab has been systematically dissecting PCa cell heterogeneity in the context of their tumor-generating, tumor-propagating, and metastatic potentials (1-9). One strategy we have employed is to frequently compare PCa cell populations bearing double-or triple-marker profiles with those expressing a single marker. For instance, we initially showed that the CD44 + 21 + PCa cell population in xenograft models is more tumorigenic than either CD44 + or 21 + cell population (3). Interestingly, we have recently observed that this phenomenon may be model-dependent (6, 9) . For example, the CD44 +
21
+ PCa cell population in LAPC9 and LAPC4 xenograft models is more tumorigenic than either CD44 + or 21 + cell population (6). However, the CD44 + 21 + PCa cell population in the DU145 model appears to be slightly less tumorigenic than either CD44 + or 21 + cell population (see Table 1 ; 9) PCa cell population in the LAPC9 but not DU145 model is more metastatic when implanted in the dorsal prostate than single marker-positive cell population. We have just recently obtained this data and are in the process of summarizing the data for publication. Figure 5e in the original proposal). Since our last year's Progress Report, Pubmed search on "HOXB9 AND prostate cancer" still just turns up one reference (10) , suggesting that either HOXB9 represents an extremely novel PCa metastasis regulator or HOXB9 might be a context-and modeldependent regulator of PCa metastasis. Our bioinformatics based correlation studies on HOXB9 mRNAs with various patient parameters revealed, surprisingly, reduced HOXB9 mRNA levels in prostate tumors vs. normal tissues in TCGA database. Moreover, only a weak upregulation of HOXB9 mRNA levels is observed in metastatic samples compared with primary tumors in all 9 eligible Oncomine datasets (see Figure 6A in last year's Progress Report). FINALLY, Kaplan-Meier survival analysis revealed discordant results that in one data set high HOXB9 mRNA levels correlated with poor patient survival whereas in two other data sets high HOXB9 mRNA levels correlated with better overall patient survival (see last year's Progress Report). These observations raise the possibility that HOXB9 regulates PCa metastasis in a context-and model-dependent manner. In the remainder 6 months, we will design several sets of experiments to test this possibility. 
C. Accomplishment of part of the goals in Aim 3. The original goal of Aim 3 is to test the hypothesis that HOXB9 represents a 'master' regulator of mPCSCs and PCa metastasis via regulating the TGF/SMADs signaling which in turn controls CSC molecules such as SPP1, MMP9, CD44, and CD24 (see
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CHANGES/PROBLEMS:
Nothing to Report
PRODUCTS:
The current project intersects with several other projects in the lab, all of which have a common goal, i.e., to dissect PCa cell heterogeneity and to elucidate the role of different
